Kyverna Therapeutics, Inc.
A clinical-stage biopharma developing CAR T-cell therapies for autoimmune diseases.
KYTX | US
Overview
Corporate Details
- ISIN(s):
- US5019761049
- LEI:
- Country:
- United States of America
- Address:
- 5980 HORTON STREET, 94608 EMERYVILLE
- Website:
- https://kyvernatx.com/
- Sector:
- Manufacturing
Description
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases. The company's approach involves engineering a patient's own T cells into Chimeric Antigen Receptor (CAR) T-cells to target and deplete B cells, which are central to the pathology of many autoimmune disorders. By adapting a technology proven in oncology, Kyverna aims to reset the immune system and achieve a durable, treatment-free remission from a single infusion. Its lead product candidate, KYV-101, is an autologous, fully human anti-CD19 CAR T-cell therapy being investigated in clinical trials for conditions including lupus nephritis and multiple sclerosis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Kyverna Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kyverna Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kyverna Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
